BRAF and colorectal carcinoma: Further, since 11–23% of TRK fusion positive colorectal carcinomas have been identified in microsatellite stable/ MMR proficient (pMMR) tumors; it reasonable to consider NTRK gene fusion testing in MSI stable/ pMMR, RAS/ BRAF V600E wild-type patients however; testing this population accounts for 40% of cases tested [53].